Dynavax Technologies Corporation (DVAX)

10,94 -0,27 (-2,45%) Ab 10:48AM EDT. Markt geöffnet.

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 408

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ryan Spencer	CEO, Interim CFO & Director	1,49M	N/A	1978
Mr. David F. Novack	President & COO	1,01M	1,51M	1962
Dr. Robert Janssen M.D.	Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs	861,52k	251,32k	1954
Ms. Kelly MacDonald	Senior VP & CFO (Leave of Absence)	788,55k	N/A	1984
Mr. Justin Burgess	Chief Accounting Officer & Controller	N/A	N/A	N/A
Mr. Jeff P. Coon	Senior VP & Chief Human Resources Officer	N/A	N/A	1963
Mr. Paul Cox	VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. John L. Slebir	Senior VP & General Counsel	N/A	N/A	1966
Mr. Donn Casale	Senior VP & Chief Commercial Officer	N/A	N/A	N/A
Dr. Dong Yu	Senior Vice President of Vaccine Research	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Corporate Governance

Dynavax Technologies Corporations ISS Governance QualityScore, Stand 1. Juni 2024, lautet 4. Die grundlegenden Scores sind Audit: 4, Vorstand: 3, Shareholderrechte: 7, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.